Bovine and porcine heparins: different drugs with similar effects on human haemodialysis
Heparins from porcine and bovine intestinal mucosa differ in their structure and also in their effects on coagulation, thrombosis and bleeding. However, they are used as undistinguishable drugs. We compared bovine and porcine intestinal heparin administered to patients undergoing a particular protoc...
Saved in:
| Published in: | BMC research notes Vol. 6; no. 1; p. 230 |
|---|---|
| Main Authors: | , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
England
BioMed Central Ltd
13-06-2013
BioMed Central |
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Heparins from porcine and bovine intestinal mucosa differ in their structure and also in their effects on coagulation, thrombosis and bleeding. However, they are used as undistinguishable drugs.
We compared bovine and porcine intestinal heparin administered to patients undergoing a particular protocol of haemodialysis. We compared plasma concentrations of these two drugs and also evaluated how they affect patients and the dialyzer used.
Compared with porcine heparin, bovine heparin achieved only 76% of the maximum plasma concentration as IU mL⁻¹. This observation is consistent with the activities observed in the respective pharmaceutical preparations. When the plasma concentrations were expressed on weight basis, bovine heparin achieved a maximum concentration 1.5 fold higher than porcine heparin. The reduced anticoagulant activity and higher concentration, on weight basis, achieved in the plasma of patients under dialysis using bovine instead of porcine heparin did not affect significantly the patients or the dialyzer used. The heparin dose is still in a range, which confers security and safety to the patients.
Despite no apparent difference between bovine and porcine intestinal heparins in the haemodialysis practice, these two types of heparins should be used as distinct drugs due to their differences in structure and biological effects.
The reduced anticoagulant activity achieved in the plasma of patients under dialysis using bovine instead of porcine heparin did not affect significantly the patients or the dialyzer. |
|---|---|
| AbstractList | Heparins from porcine and bovine intestinal mucosa differ in their structure and also in their effects on coagulation, thrombosis and bleeding. However, they are used as undistinguishable drugs. We compared bovine and porcine intestinal heparin administered to patients undergoing a particular protocol of haemodialysis. We compared plasma concentrations of these two drugs and also evaluated how they affect patients and the dialyzer used. Compared with porcine heparin, bovine heparin achieved only 76% of the maximum plasma concentration as IU mL.sup.-1. This observation is consistent with the activities observed in the respective pharmaceutical preparations. When the plasma concentrations were expressed on weight basis, bovine heparin achieved a maximum concentration 1.5 fold higher than porcine heparin. The reduced anticoagulant activity and higher concentration, on weight basis, achieved in the plasma of patients under dialysis using bovine instead of porcine heparin did not affect significantly the patients or the dialyzer used. The heparin dose is still in a range, which confers security and safety to the patients. Despite no apparent difference between bovine and porcine intestinal heparins in the haemodialysis practice, these two types of heparins should be used as distinct drugs due to their differences in structure and biological effects. The reduced anticoagulant activity achieved in the plasma of patients under dialysis using bovine instead of porcine heparin did not affect significantly the patients or the dialyzer. Background: Heparins from porcine and bovine intestinal mucosa differ in their structure and also in their effects on coagulation, thrombosis and bleeding. However, they are used as undistinguishable drugs. Methods: We compared bovine and porcine intestinal heparin administered to patients undergoing a particular protocol of haemodialysis. We compared plasma concentrations of these two drugs and also evaluated how they affect patients and the dialyzer used. Results: Compared with porcine heparin, bovine heparin achieved only 76% of the maximum plasma concentration as IU mL super(-1). This observation is consistent with the activities observed in the respective pharmaceutical preparations. When the plasma concentrations were expressed on weight basis, bovine heparin achieved a maximum concentration 1.5 fold higher than porcine heparin. The reduced anticoagulant activity and higher concentration, on weight basis, achieved in the plasma of patients under dialysis using bovine instead of porcine heparin did not affect significantly the patients or the dialyzer used. The heparin dose is still in a range, which confers security and safety to the patients. Discussion: Despite no apparent difference between bovine and porcine intestinal heparins in the haemodialysis practice, these two types of heparins should be used as distinct drugs due to their differences in structure and biological effects. Conclusions: The reduced anticoagulant activity achieved in the plasma of patients under dialysis using bovine instead of porcine heparin did not affect significantly the patients or the dialyzer. Background Heparins from porcine and bovine intestinal mucosa differ in their structure and also in their effects on coagulation, thrombosis and bleeding. However, they are used as undistinguishable drugs. Methods We compared bovine and porcine intestinal heparin administered to patients undergoing a particular protocol of haemodialysis. We compared plasma concentrations of these two drugs and also evaluated how they affect patients and the dialyzer used. Results Compared with porcine heparin, bovine heparin achieved only 76% of the maximum plasma concentration as IU mL.sup.-1. This observation is consistent with the activities observed in the respective pharmaceutical preparations. When the plasma concentrations were expressed on weight basis, bovine heparin achieved a maximum concentration 1.5 fold higher than porcine heparin. The reduced anticoagulant activity and higher concentration, on weight basis, achieved in the plasma of patients under dialysis using bovine instead of porcine heparin did not affect significantly the patients or the dialyzer used. The heparin dose is still in a range, which confers security and safety to the patients. Discussion Despite no apparent difference between bovine and porcine intestinal heparins in the haemodialysis practice, these two types of heparins should be used as distinct drugs due to their differences in structure and biological effects. Conclusions The reduced anticoagulant activity achieved in the plasma of patients under dialysis using bovine instead of porcine heparin did not affect significantly the patients or the dialyzer. Keywords: Heparin, Antithrombotic effects, Haemodialysis Doc number: 230 Abstract Background: Heparins from porcine and bovine intestinal mucosa differ in their structure and also in their effects on coagulation, thrombosis and bleeding. However, they are used as undistinguishable drugs. Methods: We compared bovine and porcine intestinal heparin administered to patients undergoing a particular protocol of haemodialysis. We compared plasma concentrations of these two drugs and also evaluated how they affect patients and the dialyzer used. Results: Compared with porcine heparin, bovine heparin achieved only 76% of the maximum plasma concentration as IU mL-1 . This observation is consistent with the activities observed in the respective pharmaceutical preparations. When the plasma concentrations were expressed on weight basis, bovine heparin achieved a maximum concentration 1.5 fold higher than porcine heparin. The reduced anticoagulant activity and higher concentration, on weight basis, achieved in the plasma of patients under dialysis using bovine instead of porcine heparin did not affect significantly the patients or the dialyzer used. The heparin dose is still in a range, which confers security and safety to the patients. Discussion: Despite no apparent difference between bovine and porcine intestinal heparins in the haemodialysis practice, these two types of heparins should be used as distinct drugs due to their differences in structure and biological effects. Conclusions: The reduced anticoagulant activity achieved in the plasma of patients under dialysis using bovine instead of porcine heparin did not affect significantly the patients or the dialyzer. BACKGROUNDHeparins from porcine and bovine intestinal mucosa differ in their structure and also in their effects on coagulation, thrombosis and bleeding. However, they are used as undistinguishable drugs. METHODSWe compared bovine and porcine intestinal heparin administered to patients undergoing a particular protocol of haemodialysis. We compared plasma concentrations of these two drugs and also evaluated how they affect patients and the dialyzer used. RESULTSCompared with porcine heparin, bovine heparin achieved only 76% of the maximum plasma concentration as IU mL⁻¹. This observation is consistent with the activities observed in the respective pharmaceutical preparations. When the plasma concentrations were expressed on weight basis, bovine heparin achieved a maximum concentration 1.5 fold higher than porcine heparin. The reduced anticoagulant activity and higher concentration, on weight basis, achieved in the plasma of patients under dialysis using bovine instead of porcine heparin did not affect significantly the patients or the dialyzer used. The heparin dose is still in a range, which confers security and safety to the patients. DISCUSSIONDespite no apparent difference between bovine and porcine intestinal heparins in the haemodialysis practice, these two types of heparins should be used as distinct drugs due to their differences in structure and biological effects. CONCLUSIONSThe reduced anticoagulant activity achieved in the plasma of patients under dialysis using bovine instead of porcine heparin did not affect significantly the patients or the dialyzer. BACKGROUND: Heparins from porcine and bovine intestinal mucosa differ in their structure and also in their effects on coagulation, thrombosis and bleeding. However, they are used as undistinguishable drugs. METHODS: We compared bovine and porcine intestinal heparin administered to patients undergoing a particular protocol of haemodialysis. We compared plasma concentrations of these two drugs and also evaluated how they affect patients and the dialyzer used. RESULTS: Compared with porcine heparin, bovine heparin achieved only 76% of the maximum plasma concentration as IU mL-1. This observation is consistent with the activities observed in the respective pharmaceutical preparations. When the plasma concentrations were expressed on weight basis, bovine heparin achieved a maximum concentration 1.5 fold higher than porcine heparin. The reduced anticoagulant activity and higher concentration, on weight basis, achieved in the plasma of patients under dialysis using bovine instead of porcine heparin did not affect significantly the patients or the dialyzer used. The heparin dose is still in a range, which confers security and safety to the patients. DISCUSSION: Despite no apparent difference between bovine and porcine intestinal heparins in the haemodialysis practice, these two types of heparins should be used as distinct drugs due to their differences in structure and biological effects. CONCLUSIONS: The reduced anticoagulant activity achieved in the plasma of patients under dialysis using bovine instead of porcine heparin did not affect significantly the patients or the dialyzer. Heparins from porcine and bovine intestinal mucosa differ in their structure and also in their effects on coagulation, thrombosis and bleeding. However, they are used as undistinguishable drugs. We compared bovine and porcine intestinal heparin administered to patients undergoing a particular protocol of haemodialysis. We compared plasma concentrations of these two drugs and also evaluated how they affect patients and the dialyzer used. Compared with porcine heparin, bovine heparin achieved only 76% of the maximum plasma concentration as IU mL⁻¹. This observation is consistent with the activities observed in the respective pharmaceutical preparations. When the plasma concentrations were expressed on weight basis, bovine heparin achieved a maximum concentration 1.5 fold higher than porcine heparin. The reduced anticoagulant activity and higher concentration, on weight basis, achieved in the plasma of patients under dialysis using bovine instead of porcine heparin did not affect significantly the patients or the dialyzer used. The heparin dose is still in a range, which confers security and safety to the patients. Despite no apparent difference between bovine and porcine intestinal heparins in the haemodialysis practice, these two types of heparins should be used as distinct drugs due to their differences in structure and biological effects. The reduced anticoagulant activity achieved in the plasma of patients under dialysis using bovine instead of porcine heparin did not affect significantly the patients or the dialyzer. |
| ArticleNumber | 230 |
| Audience | Academic |
| Author | Leite, Jr, Maurilo Lugon, Jocemir R Rembold, Simone M Tovar, Ana M F Teixeira, Lisandra A C Mourão, Paulo A S |
| AuthorAffiliation | 2 Instituto de Bioquímica Médica, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil 3 Divisão de Nefrologia, Departamento de Medicina Clínica, Universidade Federal Fluminense, Niterói, Brazil 4 Serviço de Nefrologia, Departamento de Clínica Médica, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil 1 Laboratório de Tecido Conjuntivo, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil |
| AuthorAffiliation_xml | – name: 2 Instituto de Bioquímica Médica, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil – name: 3 Divisão de Nefrologia, Departamento de Medicina Clínica, Universidade Federal Fluminense, Niterói, Brazil – name: 4 Serviço de Nefrologia, Departamento de Clínica Médica, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil – name: 1 Laboratório de Tecido Conjuntivo, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil |
| Author_xml | – sequence: 1 givenname: Ana M F surname: Tovar fullname: Tovar, Ana M F email: pmourao@hucff.ufrj.br organization: Laboratório de Tecido Conjuntivo, Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil. pmourao@hucff.ufrj.br – sequence: 2 givenname: Lisandra A C surname: Teixeira fullname: Teixeira, Lisandra A C – sequence: 3 givenname: Simone M surname: Rembold fullname: Rembold, Simone M – sequence: 4 givenname: Maurilo surname: Leite, Jr fullname: Leite, Jr, Maurilo – sequence: 5 givenname: Jocemir R surname: Lugon fullname: Lugon, Jocemir R – sequence: 6 givenname: Paulo A S surname: Mourão fullname: Mourão, Paulo A S |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/23763719$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkk1r3DAQhkVJaZJtz70VQy_NwYlk2bLUQyEJ_QgEcmlLb0KWRrsKtrSV7LT595HZdNktKRShDzTPvBpezTE68MEDQq8JPiWEszPSNqzEDcYlKyuKn6Gj7c3BzvkQHad0izEjnJMX6LCiLaMtEUfox0W4cx4K5U2xDlHP5xWsVXQ-vS-MsxYi-LEwcVqm4pcbV0Vyg-tVLCDH9JiK4IvVNKi8KhiCcaq_Ty69RM-t6hO8etwX6Nunj18vv5TXN5-vLs-vy66pBC47wU3T8gpDU9GOW6pyzURoXtvKUFHnyU1nDG9AgaWYM01UXXVWNVbYltMF-rDRXU_dAEbnYqPq5Tq6QcV7GZST-xHvVnIZ7iRlPD9bZ4GLjUDnwj8E9iM6DHJ2Vs7OSiaz71nk3WMVMfycII1ycElD3ysPYUqSUCEEYYTU_4G2mFE-_9ACvf0LvQ1T9NnOmSKYVLTaoZaqB-m8DblMPYvK84bWLWeippk6fYLKw8DgdO4q6_L9XsLJXkJmRvg9LtWUkry6-b7Pnm1YHUNKEezWPoLl3KhPGPZm99u2_J_OpA8N8eNq |
| CitedBy_id | crossref_primary_10_1038_srep35619 crossref_primary_10_1124_pr_115_011247 crossref_primary_10_1055_a_1946_0325 crossref_primary_10_1055_a_1750_1300 crossref_primary_10_1097_MJT_0000000000001191 crossref_primary_10_1155_2021_5543460 crossref_primary_10_23736_S1593_232X_23_00578_7 crossref_primary_10_1016_j_carbpol_2024_122216 crossref_primary_10_1021_acs_jmedchem_0c02019 crossref_primary_10_17116_terarkh20168812109_115 crossref_primary_10_1016_j_jpba_2015_08_017 crossref_primary_10_1002_jps_24134 crossref_primary_10_1016_j_drudis_2020_09_011 crossref_primary_10_1016_j_drudis_2014_07_004 crossref_primary_10_1055_s_0042_1745743 crossref_primary_10_1177_10760296211052293 crossref_primary_10_3389_fmed_2018_00341 crossref_primary_10_1177_1076029616643822 crossref_primary_10_1111_jth_14372 crossref_primary_10_17116_kardio202417021194 crossref_primary_10_3390_molecules22071146 crossref_primary_10_3389_fmed_2018_00360 crossref_primary_10_1016_j_jpba_2017_05_034 crossref_primary_10_1021_acsomega_4c02128 |
| Cites_doi | 10.1055/s-2001-17958 10.1055/s-0037-1614170 10.1016/j.jtcvs.2012.05.065 10.1111/j.1939-165X.2005.tb00047.x 10.1111/j.1542-4758.2011.00601.x 10.1053/j.ajkd.2012.03.017 10.1590/S0102-76382008000200004 10.1016/0003-2697(62)90095-7 10.1590/S0101-28002011000400009 10.1111/j.1365-2648.2007.04383.x 10.1002/jps.21729 10.1160/TH09-11-0761 10.1007/s11239-008-0280-4 10.1074/jbc.M109.005702 10.1016/j.athoracsur.2011.09.048 10.1160/TH-11-07-0518 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2013 BioMed Central Ltd. 2013 Tovar et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Copyright © 2013 Tovar et al.; licensee BioMed Central Ltd. 2013 Tovar et al.; licensee BioMed Central Ltd. |
| Copyright_xml | – notice: COPYRIGHT 2013 BioMed Central Ltd. – notice: 2013 Tovar et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. – notice: Copyright © 2013 Tovar et al.; licensee BioMed Central Ltd. 2013 Tovar et al.; licensee BioMed Central Ltd. |
| DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION IOV 3V. 7X7 7XB 88E 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M1P M7P PIMPY PQEST PQQKQ PQUKI PRINS 7X8 7U7 C1K 5PM |
| DOI | 10.1186/1756-0500-6-230 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Opposing Viewpoints (Gale) ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection AUTh Library subscriptions: ProQuest Central ProQuest Natural Science Collection ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) Biological Science Database Publicly Available Content Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic Toxicology Abstracts Environmental Sciences and Pollution Management PubMed Central (Full Participant titles) |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Publicly Available Content Database ProQuest Central Student ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest Natural Science Collection ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Biological Science Collection ProQuest Medical Library (Alumni) ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest Central (Alumni) MEDLINE - Academic Toxicology Abstracts Environmental Sciences and Pollution Management |
| DatabaseTitleList | Toxicology Abstracts Publicly Available Content Database MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: ECM name: MEDLINE url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 1756-0500 |
| EndPage | 230 |
| ExternalDocumentID | oai_biomedcentral_com_1756_0500_6_230 3004350511 A534786943 10_1186_1756_0500_6_230 23763719 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | Rio de Janeiro Brazil |
| GeographicLocations_xml | – name: Rio de Janeiro Brazil |
| GroupedDBID | --- -A0 0R~ 23N 2WC 3V. 4.4 53G 5GY 5VS 6J9 7X7 88E 8FE 8FH 8FI 8FJ AAFWJ AAJSJ ABDBF ABUWG ACGFO ACGFS ACIHN ACMJI ACPRK ACRMQ ADBBV ADINQ ADRAZ ADUKV AEAQA AFKRA AFPKN AHBYD AHMBA AHSBF AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BBNVY BCNDV BENPR BFQNJ BHPHI BMC BPHCQ BVXVI C24 C6C CCPQU CGR CS3 CUY CVF DIK E3Z EBD EBLON EBS ECM EIF EJD EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 H13 HCIFZ HMCUK HYE IAO IEA IHR INH INR IOV ITC KQ8 LK8 M1P M48 M7P MK0 M~E NPM O5R O5S OK1 P2P PGMZT PIMPY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV SBL SOJ SV3 TR2 TUS UKHRP ~8M AAYXX CITATION 7XB 8FK AZQEC DWQXO GNUQQ K9. PQEST PQUKI PRINS 7X8 7U7 C1K ABVAZ AFGXO AFNRJ 5PM |
| ID | FETCH-LOGICAL-b5290-b98d57820e523b8f3a75619c84f2d394d398dbdd85eaef3086c1a42bfa5f9f783 |
| IEDL.DBID | RPM |
| ISSN | 1756-0500 |
| IngestDate | Tue Sep 17 21:25:11 EDT 2024 Wed May 22 07:14:15 EDT 2024 Fri Oct 25 04:46:56 EDT 2024 Fri Oct 25 00:39:50 EDT 2024 Thu Oct 10 16:08:27 EDT 2024 Tue Nov 19 21:29:37 EST 2024 Tue Nov 12 23:34:59 EST 2024 Sat Sep 28 21:07:01 EDT 2024 Thu Nov 21 22:21:02 EST 2024 Sat Sep 28 07:58:58 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-b5290-b98d57820e523b8f3a75619c84f2d394d398dbdd85eaef3086c1a42bfa5f9f783 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Article-2 ObjectType-Feature-1 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3688204/ |
| PMID | 23763719 |
| PQID | 1371012326 |
| PQPubID | 55247 |
| PageCount | 1 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_3688204 biomedcentral_primary_oai_biomedcentral_com_1756_0500_6_230 proquest_miscellaneous_1399916114 proquest_miscellaneous_1370638376 proquest_journals_1371012326 gale_infotracmisc_A534786943 gale_infotracacademiconefile_A534786943 gale_incontextgauss_IOV_A534786943 crossref_primary_10_1186_1756_0500_6_230 pubmed_primary_23763719 |
| PublicationCentury | 2000 |
| PublicationDate | 20130613 |
| PublicationDateYYYYMMDD | 2013-06-13 |
| PublicationDate_xml | – month: 6 year: 2013 text: 20130613 day: 13 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | BMC research notes |
| PublicationTitleAlternate | BMC Res Notes |
| PublicationYear | 2013 |
| Publisher | BioMed Central Ltd BioMed Central |
| Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central |
| References | 8737629 - Arzneimittelforschung. 1996 May;46(5):472-7 18820778 - Rev Bras Cir Cardiovasc. 2008 Apr-Jun;23(2):169-74 22189808 - J Bras Nefrol. 2011 Dec;33(4):442-7 22560830 - Am J Kidney Dis. 2012 Sep;60(3):473-86 22093600 - Hemodial Int. 2011 Oct;15 Suppl 1:S43-8 18931979 - J Thromb Thrombolysis. 2008 Dec;26(3):218-28 11154113 - Thromb Haemost. 2000 Dec;84(6):1052-6 22743176 - J Thorac Cardiovasc Surg. 2012 Oct;144(4):944-950.e3 20216993 - Thromb Haemost. 2010 May;103(5):1005-15 19403528 - J Biol Chem. 2009 Jul 10;284(28):18790-800 22437650 - Thromb Haemost. 2012 May;107(5):903-15 11668416 - Semin Thromb Hemost. 2001 Oct;27(5):473-82 13971270 - Anal Biochem. 1962 Oct;4:330-4 22226493 - Ann Thorac Surg. 2012 Mar;93(3):878-82 19642166 - J Pharm Sci. 2009 Nov;98(11):4017-26 16134071 - Vet Clin Pathol. 2005 Sep;34(3):237-42 17727406 - J Adv Nurs. 2007 Sep;59(6):644-53 CE Gruenwald (2256_CR9) 2012; 93 Z Zhang (2256_CR17) 2009; 98 M Yavari (2256_CR1) 2008; 26 M Guerrini (2256_CR8) 2001; 27 AMF Tovar (2256_CR6) 2012; 107 A Diquélou (2256_CR14) 2005; 34 T Bitter (2256_CR15) 1962; 4 RC Sesso (2256_CR12) 2011; 33 JI Shen (2256_CR3) 2012; 60 MO Castro (2256_CR13) 2009; 284 KA Arsenault (2256_CR10) 2012; 144 RS Aquino (2256_CR5) 2010; 103 B Casu (2256_CR7) 1996; 46 H Noble (2256_CR11) 2007; 59 A Davenport (2256_CR2) 2011; 15 B Mulloy (2256_CR4) 2000; 84 EI Melo (2256_CR16) 2008; 23 |
| References_xml | – volume: 27 start-page: 473 year: 2001 ident: 2256_CR8 publication-title: Sem Thromb Hemost doi: 10.1055/s-2001-17958 contributor: fullname: M Guerrini – volume: 84 start-page: 1052 year: 2000 ident: 2256_CR4 publication-title: Thromb Haemost doi: 10.1055/s-0037-1614170 contributor: fullname: B Mulloy – volume: 46 start-page: 472 year: 1996 ident: 2256_CR7 publication-title: Arzneimittelforschung contributor: fullname: B Casu – volume: 144 start-page: 944 year: 2012 ident: 2256_CR10 publication-title: J Thorac Cardiovasc Surg doi: 10.1016/j.jtcvs.2012.05.065 contributor: fullname: KA Arsenault – volume: 34 start-page: 237 year: 2005 ident: 2256_CR14 publication-title: Vet Clin Pathol doi: 10.1111/j.1939-165X.2005.tb00047.x contributor: fullname: A Diquélou – volume: 15 start-page: S43 issue: S1 year: 2011 ident: 2256_CR2 publication-title: Hemodial Int doi: 10.1111/j.1542-4758.2011.00601.x contributor: fullname: A Davenport – volume: 60 start-page: 473 year: 2012 ident: 2256_CR3 publication-title: Am J Kidney Dis doi: 10.1053/j.ajkd.2012.03.017 contributor: fullname: JI Shen – volume: 23 start-page: 169 year: 2008 ident: 2256_CR16 publication-title: Rev Bras Cir Cardiovasc doi: 10.1590/S0102-76382008000200004 contributor: fullname: EI Melo – volume: 4 start-page: 330 year: 1962 ident: 2256_CR15 publication-title: Anal Biochem doi: 10.1016/0003-2697(62)90095-7 contributor: fullname: T Bitter – volume: 33 start-page: 442 year: 2011 ident: 2256_CR12 publication-title: J Bras Nefrol doi: 10.1590/S0101-28002011000400009 contributor: fullname: RC Sesso – volume: 59 start-page: 644 year: 2007 ident: 2256_CR11 publication-title: J Adv Nurs doi: 10.1111/j.1365-2648.2007.04383.x contributor: fullname: H Noble – volume: 98 start-page: 4017 year: 2009 ident: 2256_CR17 publication-title: J Pharm Sci doi: 10.1002/jps.21729 contributor: fullname: Z Zhang – volume: 103 start-page: 1005 year: 2010 ident: 2256_CR5 publication-title: Thromb Haemost doi: 10.1160/TH09-11-0761 contributor: fullname: RS Aquino – volume: 26 start-page: 218 year: 2008 ident: 2256_CR1 publication-title: J Thromb Thrombolysis doi: 10.1007/s11239-008-0280-4 contributor: fullname: M Yavari – volume: 284 start-page: 18790 year: 2009 ident: 2256_CR13 publication-title: J Biol Chem doi: 10.1074/jbc.M109.005702 contributor: fullname: MO Castro – volume: 93 start-page: 878 year: 2012 ident: 2256_CR9 publication-title: Ann Thorac Surg doi: 10.1016/j.athoracsur.2011.09.048 contributor: fullname: CE Gruenwald – volume: 107 start-page: 903 year: 2012 ident: 2256_CR6 publication-title: Thromb Haemost doi: 10.1160/TH-11-07-0518 contributor: fullname: AMF Tovar |
| SSID | ssj0061881 |
| Score | 2.1371021 |
| Snippet | Heparins from porcine and bovine intestinal mucosa differ in their structure and also in their effects on coagulation, thrombosis and bleeding. However, they... Background Heparins from porcine and bovine intestinal mucosa differ in their structure and also in their effects on coagulation, thrombosis and bleeding.... Doc number: 230 Abstract Background: Heparins from porcine and bovine intestinal mucosa differ in their structure and also in their effects on coagulation,... BACKGROUNDHeparins from porcine and bovine intestinal mucosa differ in their structure and also in their effects on coagulation, thrombosis and bleeding.... Background: Heparins from porcine and bovine intestinal mucosa differ in their structure and also in their effects on coagulation, thrombosis and bleeding.... BACKGROUND: Heparins from porcine and bovine intestinal mucosa differ in their structure and also in their effects on coagulation, thrombosis and bleeding.... |
| SourceID | pubmedcentral biomedcentral proquest gale crossref pubmed |
| SourceType | Open Access Repository Aggregation Database Index Database |
| StartPage | 230 |
| SubjectTerms | Animals Anticoagulants Cattle Comparative analysis Drug dosages Drug therapy Drugs Health aspects Heart surgery Hemodialysis Heparin Heparin - blood Heparin - pharmacology Humans Magnetic Resonance Spectroscopy Patients Pharmaceutical Preparations Pharmaceuticals Renal Dialysis Swine Thrombosis |
| SummonAdditionalLinks | – databaseName: BiomedCentral dbid: RBZ link: http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB7RIiQuvB-BggxCAg4RSewkNpxaaFUuIPFSxcVyYru7UutUTXPg3zOTZFd1qZAQh5w8iZ3x2J4vmfkG4IVqai5q61Jf1lkqZMFTpZxP0TlppfSlzThlI-9_rT8dyA-7RJPz-vI_-Lms3uD5hpi3zBDlpOgvb8BVRAyCjPnLzs_VplvlcqxHuhaeWXwuecCFzPaj6EC6uC2fO5fimMlzh9DezX8Y_i24MXuabHsyjdtwxYU7cG2qPfnrLhzs0LcEx0ywDH1w-r_OFo5qEob-LVvVTTlj9nQ47Bl9rmX98niJQJjNMSCsC2ws8ccWxh13lIFC9Cb34Pve7rf3--lcZiFtykJlaaOkJVL7zCEobaTnBoecq1YKX1iuBF7SNtbK0hnnOWKgNjeiaLwpvfK15PdhM3TBPQTmC1c7SjqphMNJctKY0gkiyGkLdMREAu8i3euTiVJDE8l13ILrTZPuNOlOVxp1l8Cr1UytbxwxjKz-FH1OM6mJ4SJQCM2hGfpef_z8Q2-XaJyyUoIn8HIW8h322Zo5IwHfhUixIsmtSBKXYBs3rwxGz1tAr3Ne56PDWiXwbN1Md1JYW3DdMMqQy4ib_N9kRh8ecWsCDyYbXL89hTRhNyqBOrLOSK9xS1guRhJxXiG2ysSj_5qRx3C9mMqDpDnfgs2z08E9gY3eDk_H5fkbdXEztA priority: 500 providerName: BioMedCentral |
| Title | Bovine and porcine heparins: different drugs with similar effects on human haemodialysis |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/23763719 https://www.proquest.com/docview/1371012326 https://search.proquest.com/docview/1370638376 https://search.proquest.com/docview/1399916114 http://dx.doi.org/10.1186/1756-0500-6-230 https://pubmed.ncbi.nlm.nih.gov/PMC3688204 |
| Volume | 6 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELbYSkhcEG8CpTIICS7pJrGT2OXUllblwEO8VHGxnNjurtR1qqZ76L9nxklWNUgcOCQXj5XYnom_cWa-IeS1bGrGa2NTV9ZZykXBUimtSwGctEK40mQMs5FPvtWfTsX7I6TJKadcmBC03zbLXX--2vXLRYitvFi18ylObP7l4yGrABdmfD4jM8CGk4s-fH6rXIh85PDJRTWH7RFc5jIDJykFuI3kv2hTNVLrRCnu59HO9Of3-cYGFQdP3tiNju-RuyOMpPvD694nt6x_QG4PhSWvH5LTAzwosFR7QwFg489zurBYcND3e3QqinJFzeX6rKd4Fkv75WoJXi4dAzxo52mo30cX2q46TC9B7pJH5Mfx0ffDk3SsoZA2ZSGztJHCIGN9ZsHjbIRjGuYjl63grjBMcriEaYwRpdXWMXBw2lzzonG6dNLVgj0mW77z9imhrrC1xYySilsuuRVal5Yj-01bAMriCXkXzae6GPgyFDJYxy1gTAoXRuHCqErBwiTk7TT7m47BQRHV36KvcHUU0ld4jI850-u-Vx8-_1T7JWieqCRnCXkzCrkOntnqMd0AxoKMV5HkdiQJ9tXGzZMSqNG-e5WDAgU0WiXk5aYZe2LMmrfdOsggHgRt-5dMAOjglCbkyaBXm9FPepqQOtK4aF7jFjCYwBA-Gsiz_-75nNwphrofac62ydbV5dq-ILPerHfCqQXcvx782gmW9xsXgzE6 |
| link.rule.ids | 108,230,315,729,782,786,866,887,24946,27933,27934,53800,53802,75821,75822 |
| linkProvider | National Library of Medicine |
| linkToHtml | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELZoEYJLedNAAYOQ4JJuEjuJDadSWm1FW5AoqDfLie3uSl2naroH_j0zeaxqkDj0sKcZa-XMjP1NMvMNIe9kVTJeGhu7vExiLjIWS2ldDOCkFsLlJmHYjTz9UR6fii97SJOTj70wXdF-Xc23_fli289nXW3lxaKejHVik-9Hu6wAXJjwyRq5DfGaJGOS3h_ARSpEOrD4pKKYwAUJSXOeQJoUA-BG-l-MqhLJdYIm9_Pgbvr7hL52RYXlk9fuo_37N9zJA7IxAFC604sfklvWPyJ3-pGUvx-T08_4isFS7Q0FaI6f3enM4qhC336k4ziVK2oul2ctxbe4tJ0v5pAf06E0hDaedpP_6EzbRYONKch68oT83N872Z3Gw_SFuMozmcSVFAa57hMLuWolHNPwHFNZC-4ywySHnzCVMSK32joGqVGdap5VTudOulKwp2TdN95uEuoyW1rsRSm45ZJboXVuOfLm1BngMx6RT4Ed1EXPtKGQ-zqUQBgqNKhCg6pCgUEj8mG02mphl9qI4l_Vt2hVhcQXHitrzvSybdXBt19qJwefFYXkLCLvByXXwH_WemhUgL0gV1aguRVoQmTWoXh0HjWcDK1KwfE6HFtE5M1KjCux2s3bZtnpIJIEL_2fTgftIZ2NyLPeH1e7H_07ImXgqcFzDSXgoB23-OCQz2-88jW5Oz05OlSHB8dfX5B7WT89JE7ZFlm_ulzal2StNctXXcT-Aen3RL0 |
| linkToPdf | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELZoEYgL70eggEFIcEnzchIbTqXtqhVQKgFVb5YT292Vus6qaQ78e2byWNUgcYBDTh4rcmbG_saZ-YaQN6IqM1ZqE9q8jEPG0ywUwtgQwEnNuc11nGE18sG38uiU7-0jTc661VeftF9Xi213vtx2i3mfW7la1tGUJxYdf9nNCsCFMYtW2kYb5Dr4bJxOgfqwCRcJ58nI5JPwIoJDEgLnPIZQKQTQjRTA6FklEux4he7n3vn0-y595ZjyUyivnEmzO_-xmrvk9ghE6c4gco9cM-4-uTG0pvz5gJx-xKsGQ5XTFCA6_n6nc4MtC137nk5tVS6pvujOWoq3ubRdLBcQJ9MxRYQ2jvYdAOlcmWWDBSrIfvKQ_Jjtf989CMcuDGGVpyIOK8E1ct7HBmLWittMwbdMRM2ZTXUmGDxcV1rz3ChjMwiR6kSxtLIqt8KWPHtENl3jzBNCbWpKgzUpBTNMMMOVyg1D_pw6BZzGAvLB04VcDYwbEjmw_RFwR4lKlahUWUhQakDeTZpbT-xDHF78KfoaNSuRAMNhhs2Z6tpWHn49kTs52C4vBMsC8nYUsg28s1ZjwQKsBTmzPMktTxI8tPaHJwOS4w7RygSMr8ezRUBerYdxJma9OdN0vQwiSrDUv8n0EB_C2oA8HmxyvfrJxgNSetbqfVd_BIy05xgfjfLpP898SW4e783k58OjT8_IrXRoIhIm2RbZvLzozHOy0eruRe-0vwAJQUc9 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Bovine+and+porcine+heparins%3A+different+drugs+with+similar+effects+on+human+haemodialysis&rft.jtitle=BMC+research+notes&rft.au=Tovar%2C+Ana+MF&rft.au=Teixeira%2C+Lisandra+AC&rft.au=Rembold%2C+Simone+M&rft.au=Leite%2C+Maurilo+Jr&rft.date=2013-06-13&rft.issn=1756-0500&rft.eissn=1756-0500&rft.volume=6&rft.issue=1&rft.spage=230&rft.epage=230&rft_id=info:doi/10.1186%2F1756-0500-6-230&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1756-0500&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1756-0500&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1756-0500&client=summon |